Drug intelligence / Profile preview

HAT-11

Development stage: Preclinical
Lead developer: DRC
Administration: Topical

Overview

HAT-11 is a topical medical device being developed by DRC (Dermatological Research Center Co., Ltd.) for the treatment of dermatitis and infectious diseases. The product is designed as a sheet formulation, intended for application to the skin. It is currently undergoing preclinical and validation trials in Japan. As a medical device, HAT-11 likely functions through physical or mechanical mechanisms to manage skin conditions, though the specific mode of action has not been publicly disclosed in available pipeline documentation.

Beyond the preview

Go deeper on HAT-11.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on HAT-11.

Explore the full profile